Drug balloon
By setting a concave storage part on the surface of the drug balloon and using precision printing technology to enhance the firmness of the drug coating, the problems of poor passing through the drug balloon and coating loss in complex vascular lesions are solved, achieving more efficient drug release and hemodynamic effects.
Patent Information
- Application Number
- CN202420018063.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-03
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2034-01-03
Smart Images

Figure CN222075685U_ABST
Abstract
Description
Technical Field
[0001] The utility model relates to a balloon catheter, in particular to a drug balloon, and belongs to the technical field of medical devices. Background Art
[0002] There are currently three main interventional treatment methods for vascular stenosis: simple balloon dilatation, stent implantation, and drug-eluting balloon. Among them, drug-eluting balloon is an upgrade of simple balloon treatment and uses a single drug coating. Compared with stent implantation, drug-eluting balloon has the following advantages: uniform drug distribution, which can release the drug evenly to the endothelium of the blood vessel wall; no polymer coating, which can avoid the inflammatory response induced by the polymer coating and reduce the occurrence of late thrombosis; no need to implant stents, which can avoid foreign body placement, preserve the original anatomical structure of the blood vessels, and reserve the opportunity for follow-up treatment for patients when necessary; it can shorten the dual antiplatelet time and reduce the incidence of bleeding complications; it is simple to operate, has good permeability, and a high surgical success rate.
[0003] Although drug-eluting balloons have the above advantages, there are still some problems. For example, the surface of drug-eluting balloons is coated with drug coating, which increases the volume and makes it difficult to reach distal small blood vessels or complex curved lesions. The thrombus is severely calcified at the narrow part of the blood vessel, and the thrombus still exists or remains in a large amount after balloon expansion. The drug on the surface of the balloon is easily shed during balloon delivery, expansion, pressure relief, and withdrawal (including being washed away by high-speed blood flow and friction loss with the blood vessel wall). The shed drug coating, especially some carriers, is not soluble in the blood and will exist in the form of large particles. It will flow to the distal small blood vessels with the blood, and there is a great risk of occluding the distal blood vessels. Therefore, drug-eluting balloons with ordinary structures and a single drug coating are increasingly unable to meet the current treatment of complex lesions. Utility Model Content
[0004] The purpose of the utility model is to provide a drug balloon that solves the problems of poor permeability, low coating firmness, single performance and difficulty in breaking stubborn thrombus. The technical solution is as follows:
[0005] A drug balloon comprises a catheter, a balloon body and a coating. A concave drug storage portion is arranged on the surface of the balloon body, and the bottom cross section of the drug storage portion is an inverted triangle.
[0006] Furthermore, the medicine storage portion is in the shape of a triangular prism or a cone.
[0007] Furthermore, the depth of the drug storage portion is 0.1-50 microns; if the depth of the drug storage portion is less than 0.1 microns, the drug storage amount is insufficient, and when the capsule is filled, the protruding tip of the drug storage portion cannot break up the stubborn calcified thrombus; if the depth of the drug storage portion is greater than 50 microns, when the capsule is filled, it is difficult for the drug storage portion to bulge out, and the protruding tip of the drug storage portion may cause damage to the blood vessel.
[0008] Furthermore, when the capsule is in a filled state, the medicine storage portion changes from being concave to being convex, and the cross-section of the top of the medicine storage portion is in the shape of an equilateral triangle.
[0009] Furthermore, the depression is a radial depression, and the protrusion is a radial protrusion.
[0010] Furthermore, the depression is an axial depression, and the protrusion is an axial protrusion.
[0011] Furthermore, the material hardness of the drug storage portion is greater than the material hardness of other portions of the balloon surface.
[0012] Compared with the prior art, the beneficial effect of the utility model is that the drug balloon prepared by the preparation method of the utility model can coat the drug in the drug storage part through precision printing, the outer layer of fat-soluble drugs protects the drugs in the drug storage part, the drug coating is less affected by blood flow scouring, the loss of the drug coating during transportation is reduced, and the transfer rate of the drug coating is increased. The drug storage structure can increase the surface area of the balloon without increasing the outer diameter, improve the drug loading, and do not affect the permeability of the balloon, and can reach the distal small blood vessel lesion location. When the drug balloon is in a filled state, the drug storage part changes from concave to convex, and the convex tip can break up stubborn calcified thrombus, increase the drug release rate and hemodynamics, and make the drug release rapid and reach the lesion directly. The drug coating prepared by the utility model contains a variety of drugs, which can play multiple functions and meet various clinical requirements. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 This is a schematic diagram of the structure of the drug balloon in the inflated state;
[0014] Figure 2 This is a schematic diagram of the structure of the drug balloon in a filled state;
[0015] Figure 3 It is a schematic diagram of the structure of a drug balloon in a filled state with a drug storage portion in the shape of a triangular prism;
[0016] Figure 4 A schematic diagram of a portion of the drug coating of Example 2;
[0017] Figure 5 This is a schematic diagram of a portion of the drug coating of Example 3;
[0018] Figure 6 A schematic diagram of a portion of the drug coating of Example 4;
[0019] In the figure, 1, catheter, 2, balloon, 3, drug storage part. DETAILED DESCRIPTION
[0020] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0021] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention.
[0022] The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples are all commercially available unless otherwise specified.
[0023] The balloons used in all the embodiments and comparative examples have the same specifications: a balloon diameter of 4 mm and a balloon length of 20 mm.
[0024] Example 1
[0025] Figure 1 and Figure 2 As shown, when the balloon 2 is in an inflated state, a radially recessed drug storage portion 3 is provided on the surface of the balloon body. The balloon 2 is delivered to the site of vascular lesions and inflated to make the balloon 2 in a filled state. At this time, the radially recessed drug storage portion 3 on the surface of the balloon body bulges in the opposite direction under the action of pressure to form a radially protruding drug storage portion 3 on the surface of the balloon body. The tip of the drug storage portion 3 can break up stubborn calcified thrombi and release drugs to the affected area at the same time.
[0026] Example 2
[0027] 200 mg of heparin was dissolved in 20 ml of pure water, and 200 mg of paclitaxel was dissolved in 20 ml of anhydrous ethanol to obtain 10 mg / ml sodium heparin aqueous solution and 10 mg / ml paclitaxel ethanol solution, respectively. The sodium heparin drug solution was printed into the grooves on the balloon surface using a drug coating printing machine, and then the paclitaxel drug solution was sprayed onto the balloon surface and dried.
[0028] Example 3
[0029] 200 mg of heparin was dissolved in 20 ml of pure water, 200 mg of paclitaxel was dissolved in 20 ml of anhydrous ethanol, and 200 mg of bivalirudin was dissolved in 20 ml of anhydrous ethanol to obtain 10 mg / ml heparin sodium aqueous solution, 10 mg / ml paclitaxel ethanol solution, and 10 mg / ml bivalirudin ethanol solution, respectively. The heparin sodium and bivalirudin drug solutions were printed on the grooves on the balloon surface using a drug coating printing machine, and then the paclitaxel ethanol solution was sprayed and dried.
[0030] Example 4
[0031] 200 mg of heparin was dissolved in 20 ml of pure water, 200 mg of argatroban was dissolved in 20 ml of anhydrous ethanol, 200 mg of bivalirudin was dissolved in 20 ml of anhydrous ethanol, and 200 mg of paclitaxel was dissolved in 20 ml of anhydrous ethanol to obtain 10 mg / ml sodium heparin aqueous solution, 10 mg / ml argatroban ethanol solution, 10 mg / ml bivalirudin ethanol solution and 10 mg / ml paclitaxel ethanol solution, respectively. The first three drug solutions were printed on the grooves on the balloon surface by a drug coating printing machine, and then the paclitaxel solution was sprayed on the balloon surface and dried.
[0032] Example 5
[0033] 200 mg of paclitaxel was dissolved in 20 ml of anhydrous ethanol to obtain a 10 mg / ml paclitaxel ethanol solution. The paclitaxel solution was printed into the grooves on the balloon surface using a drug coating printing machine, and then the paclitaxel solution was sprayed onto the balloon surface and dried.
[0034] Example 6
[0035] 200 mg of heparin was dissolved in 20 ml of pure water, 200 mg of argatroban was dissolved in 20 ml of anhydrous ethanol, 200 mg of bivalirudin was dissolved in 20 ml of anhydrous ethanol, and 200 mg of paclitaxel was dissolved in 20 ml of anhydrous ethanol to obtain 10 mg / ml sodium heparin aqueous solution, 10 mg / ml argatroban ethanol solution, 10 mg / ml bivalirudin ethanol solution and 10 mg / ml paclitaxel ethanol solution, respectively. The first three drug solutions were sprayed onto the balloon surface by an ultrasonic spraying machine and dried.
[0036] Example 7
[0037] 200 mg of paclitaxel was dissolved in 20 ml of anhydrous ethanol to obtain a 10 mg / ml paclitaxel ethanol solution. The paclitaxel solution was sprayed onto the balloon surface using an ultrasonic spraying machine and dried.
[0038] Example 8
[0039] The pleated outer diameters of the drug balloon samples (diameter 4.0 mm, length 20 mm) prepared in Examples 2-5 and 6-7 were measured using a laser diameter meter. The test results are shown in the table below.
[0040] Table 1 Balloon pleating outer diameter test results
[0041] Group Pleated outer diameter (mm) Example 1 1.10 Example 2 1.12 Example 3 1.14 Example 4 1.07 Comparative Example 1 1.20 Comparative Example 2 1.16
[0042] The drug balloon samples prepared in Examples 2-5 and 6-7 were divided into groups a, b, c, and d. The drug balloons in group a were directly tested for drug content m1. Group b was tested in vitro using a model to simulate the use of drug balloons in the human body. A 1:1 human pipeline model was used, and a guide catheter was used as the delivery path. The end of the pipeline model was connected to a release medium (PBS buffer containing 85% ethanol), and a peristaltic pump was used to control the water flow rate. The drug balloons in group b were delivered to the designated blood vessel position through a guide guide wire, the drug balloons were withdrawn, and then the balloon part was cut off from the end of the pipeline and dried, placed in a glass container and a quantitative solvent was added, and after ultrasonic vibration, the drug content m2 was measured. The drug balloons in group c reached the designated blood vessel position through a guide guide wire, and then the balloons were expanded, and a pressure of 10 atm was maintained for 60 seconds, and the drug balloons were withdrawn. Then the balloon part was cut off from the end of the pipeline and dried, and the drug content m3 was measured. During the simulated use of the drug balloon in group B, the eluate produced was collected by a particle analyzer, and 50 ml of the eluate was tested by the light obstruction method in the insoluble particle inspection method (0903) of the 2020 edition of the Pharmacopoeia of the People's Republic of China. Liquid chromatography method to measure drug content:
[0043] The test results are shown in the table below.
[0044] Table 2 Drug coating firmness test results
[0045]
[0046]
[0047] Table 3 Drug coating simulation delivery and release results
[0048]
[0049] Note: Conveying loss rate = (m2-m1) / m1×100%; release rate = (m3-m1) / m1×100%
[0050] The above test results show that the drug balloon of the utility model enhances the firmness of the coating, reduces the loss of drug during the delivery process, and at the same time, the drug can be released to the tissue relatively faster during the expansion process.
[0051] Example 9
[0052] A method for preparing a drug balloon comprises the following steps:
[0053] Step 1) dissolving the active drug in respective drug solvents, and obtaining a drug coating solution after ultrasonic vibration;
[0054] Step 2) inflating the drug balloon having a drug storage portion on the surface of the balloon for standby use;
[0055] Step 3) coating the obtained drug coating solution on the surface of the balloon and coating it in the drug storage part by precision printing;
[0056] Step 4) After the drug coating solution on the balloon surface and in the drug storage part is dried, a second layer of drug coating solution is applied to the balloon surface and in the drug storage part to obtain a drug-coated drug balloon.
[0057] The embodiments described above are only preferred embodiments for fully illustrating the present invention, but the present invention is not limited to the above-mentioned specific implementation modes, which are merely illustrative and not restrictive. Under the guidance of the present invention, ordinary technicians in this field can make many forms without departing from the scope of protection of the present invention and the claims, all of which are within the protection of the present invention.
Claims
1. A drug balloon, comprising a catheter, a balloon body and a coating, characterized in that: A concave medicine storage portion (3) is provided on the surface of the capsule (2), and the bottom cross-section of the medicine storage portion (3) is in the shape of an inverted triangle. When the capsule (2) is in a filled state, the medicine storage portion (3) changes from being concave to being convex, and the top cross-section of the medicine storage portion (3) is in the shape of an equilateral triangle.
2. A drug balloon according to claim 1, characterized in that: The medicine storage portion (3) is in the shape of a triangular prism or a cone.
3. A drug balloon according to claim 1, characterized in that: The depth of the drug storage portion (3) is 0.1-50 microns.
4. A drug balloon according to claim 1, characterized in that: The depression is a radial depression, and the protrusion is a radial protrusion.
5. The drug balloon according to claim 1, characterized in that: The depression is an axial depression, and the protrusion is an axial protrusion.
